#USA #Huntsville #Discovery Life Sciences #Cancer Biomarkers #Mindpeak

Discovery Life Sciences and Mindpeak: A New Era in Cancer Biomarker Testing

In an era where artificial intelligence (AI) is transforming numerous sectors, its application in the medical realm is particularly promising. Recently, Discovery Life Sciences, a leader in biological sample collection and laboratory services, announced a significant partnership with Mindpeak, a prominent player in digital pathology powered by AI. Together, they aim to tackle one of the most enduring challenges in clinical trials: the inconsistent interpretation of cancer biomarkers among pathologists.

The challenge of accurately interpreting biomarkers has long plagued the clinical development landscape, leading to variability in patient stratification. This inconsistency not only complicates decision-making regarding the continuation of studies but also undermines the confidence in therapeutic developments based on these critical data points. By joining forces, Discovery and Mindpeak intend to integrate AI-enhanced digital image analysis into pathology services that cater to immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.

Enhancing Biomarker Analysis

The collaboration aims to bolster biomedical research and clinical investigations by improving biomarker quantification and observer concordance. This is crucial as it will help diminish the inherent variability, mitigate risks associated with biomarker-based trials, and reinforce confidence in pivotal development decisions.

Mindpeak’s AI platform will be combined with Discovery’s robust tissue biomarker services to facilitate precise analysis of IHC and mIF samples. The AI technology is envisioned as a safety tool in the biopharmaceutical industry, enhancing consistency in how pathologists interpret complex biological data. Key components of this integration include AI-driven pathology workflows, training sessions for pathologists through Mindpeak’s peakAcademy, and AI-guided microdissection algorithms that isolate specific tissue regions with remarkable accuracy.

Discovery Life Sciences contributes a substantial clinical infrastructure to this partnership. Established in 2008, their Biomarker Academy has educated over 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Currently, Discovery supports over 2,000 clinical trial programs, with approximately 350 of them active, having completed more than 35 studies compliant with IVDR regulations across 16 EU countries involving 25 biomarkers in the last four years.

As Greg Herrema, CEO of Discovery Life Sciences, states,